Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.

Sulfonylureas as add-on therapy to metformin are associated with increased risk of all-cause mortality and major hypoglycemic episodes compared with 'other' OHAs. Post hoc analysis suggests newer OHAs may be preferred to sulfonylureas as second-line therapy for glycemic control.